FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205938987> ?p ?o ?g. }

• W3205938987 endingPage "4637" @default.
• W3205938987 startingPage "4624" @default.
• W3205938987 abstract "Post-transplant lymphoproliferative disorders (PTLD) are among the most serious complications after solid organ transplantation (SOT). Monomorphic diffuse large B-cell lymphoma (DLBCL) is the most common subtype of PTLD. Historically, outcomes of PTLD have been poor with high mortality rates and allograft loss, although this has improved in the last 10 years. Most of our understanding about PTLD DLBCL is extrapolated from studies in non-PTLD DLBCL, and while several clinical factors have been identified and validated for predicting non-PTLD DLBCL outcomes, the molecular profile of PTLD DLBCL has not yet been characterized. Compartment-specific metabolic reprograming has been described in non-PTLD DLBCL with a lactate uptake metabolic phenotype with high monocarboxylate transporter 1 (MCT1) expression associated with worse outcomes. The aim of our study was to compare the outcomes of PTLD in our transplant center to historic cohorts, as well as study a subgroup of our PTLD DLBCL tumors and compare metabolic profiles with non-PTLD DLBCL. We performed a retrospective single institution study of all adult patients who underwent a SOT between the years 1992-2018, who were later diagnosed with PTLD. All available clinical information was extracted from the patients' medical records. Tumor metabolic markers were studied in a subgroup of PTLD DLBCL and compared to a group of non-PTLD DLBCL. Thirty patients were diagnosed with PTLD following SOT in our center. Median time from SOT to PTLD diagnosis was 62.8 months (IQR 7.6; 134.4), with 37% of patients diagnosed with early PTLD, and 63% with late PTLD. The most common PTLD subtype was DLBCL. Most patients were treated with reduction of their immunosuppression (RIS) including a group who were switched from calcineurin inhibitor (CNI) to mTOR inhibitor based IS, in conjunction with standard anti-lymphoma chemoimmunotherapy. Progression free survival of the PTLD DLBCL cohort was calculated at 86% at 1 year, and 77% at 3 and 5-years, with overall survival of 86% at 1 and 3-years, and 75% at 5 years. Death censored allograft survival in the kidney cohort was 100% at 1 year, and 93% at 3, 5 and 10 years. MCT1 H scores were significantly higher in a subset of the non-PTLD DLBCL patients than in a PTLD DLBCL cohort. Our data is concordant with improved PTLD outcomes in the last 10 years. mTOR inhibitors could be an alternative to CNI as a RIS strategy. Finally, PTLD DLBCL may have a distinct metabolic profile with reduced MCT1 expression compared to non-PTLD DLBCL, but further studies are needed to corroborate our limited cohort findings and to determine if a specific metabolic profile is associated with outcomes." @default.
• W3205938987 created "2021-10-25" @default.
• W3205938987 creator A5013765443 @default.
• W3205938987 creator A5034652122 @default.
• W3205938987 creator A5055841016 @default.
• W3205938987 creator A5075186864 @default.
• W3205938987 creator A5075267688 @default.
• W3205938987 creator A5075945886 @default.
• W3205938987 creator A5077605764 @default.
• W3205938987 creator A5086262282 @default.
• W3205938987 creator A5089366449 @default.
• W3205938987 date "2021-01-01" @default.
• W3205938987 modified "2023-10-09" @default.
• W3205938987 title "Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature." @default.
• W3205938987 cites W1533246992 @default.
• W3205938987 cites W1544269146 @default.
• W3205938987 cites W1586534080 @default.
• W3205938987 cites W1687884806 @default.
• W3205938987 cites W1696276358 @default.
• W3205938987 cites W1839494253 @default.
• W3205938987 cites W1871078739 @default.
• W3205938987 cites W1925602349 @default.
• W3205938987 cites W1964106115 @default.
• W3205938987 cites W1965862969 @default.
• W3205938987 cites W1966304850 @default.
• W3205938987 cites W1979544950 @default.
• W3205938987 cites W2024382442 @default.
• W3205938987 cites W2025321012 @default.
• W3205938987 cites W2025932421 @default.
• W3205938987 cites W2037183009 @default.
• W3205938987 cites W2037926194 @default.
• W3205938987 cites W2052038595 @default.
• W3205938987 cites W2054280865 @default.
• W3205938987 cites W2061062185 @default.
• W3205938987 cites W2062430887 @default.
• W3205938987 cites W2072351874 @default.
• W3205938987 cites W2088807765 @default.
• W3205938987 cites W2091616383 @default.
• W3205938987 cites W2110467543 @default.
• W3205938987 cites W2112825838 @default.
• W3205938987 cites W2116721864 @default.
• W3205938987 cites W2125231116 @default.
• W3205938987 cites W2128867940 @default.
• W3205938987 cites W2129691127 @default.
• W3205938987 cites W2137858837 @default.
• W3205938987 cites W2137960096 @default.
• W3205938987 cites W2138604360 @default.
• W3205938987 cites W2151139118 @default.
• W3205938987 cites W2162790232 @default.
• W3205938987 cites W2170308172 @default.
• W3205938987 cites W2208016779 @default.
• W3205938987 cites W2268578514 @default.
• W3205938987 cites W2271823683 @default.
• W3205938987 cites W2295409074 @default.
• W3205938987 cites W2310716991 @default.
• W3205938987 cites W2345381093 @default.
• W3205938987 cites W2488473557 @default.
• W3205938987 cites W2578876390 @default.
• W3205938987 cites W2604433773 @default.
• W3205938987 cites W2744261860 @default.
• W3205938987 cites W2751075585 @default.
• W3205938987 cites W2757606478 @default.
• W3205938987 cites W2761781078 @default.
• W3205938987 cites W2784405670 @default.
• W3205938987 cites W2786571997 @default.
• W3205938987 cites W2801400541 @default.
• W3205938987 cites W2801763724 @default.
• W3205938987 cites W2902942415 @default.
• W3205938987 cites W2911188335 @default.
• W3205938987 cites W2915134459 @default.
• W3205938987 cites W2921072067 @default.
• W3205938987 cites W2943984860 @default.
• W3205938987 cites W2950049436 @default.
• W3205938987 cites W3008934723 @default.
• W3205938987 cites W3016044607 @default.
• W3205938987 cites W3037152006 @default.
• W3205938987 cites W3114692785 @default.
• W3205938987 cites W3130295600 @default.
• W3205938987 cites W3134205746 @default.
• W3205938987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8493408" @default.
• W3205938987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34659910" @default.
• W3205938987 hasPublicationYear "2021" @default.
• W3205938987 type Work @default.
• W3205938987 sameAs 3205938987 @default.
• W3205938987 citedByCount "0" @default.
• W3205938987 crossrefType "journal-article" @default.
• W3205938987 hasAuthorship W3205938987A5013765443 @default.
• W3205938987 hasAuthorship W3205938987A5034652122 @default.
• W3205938987 hasAuthorship W3205938987A5055841016 @default.
• W3205938987 hasAuthorship W3205938987A5075186864 @default.
• W3205938987 hasAuthorship W3205938987A5075267688 @default.
• W3205938987 hasAuthorship W3205938987A5075945886 @default.
• W3205938987 hasAuthorship W3205938987A5077605764 @default.
• W3205938987 hasAuthorship W3205938987A5086262282 @default.
• W3205938987 hasAuthorship W3205938987A5089366449 @default.
• W3205938987 hasConcept C126322002 @default.
• W3205938987 hasConcept C143998085 @default.
• W3205938987 hasConcept C167135981 @default.

• next